Market Size (2016)
2016
$20.71B
Vertical: HealthcareBase Year: 201811 Sections
Market Size (2016)
2016
$20.71B
Projected (2025)
2025
$44.14B
CAGR (2016–2025)
8.8%
8.8%Key Players
108+
Fertility services are procedures or treatments used to cure genetic and fertility issues and assist with conception. These services include assisted reproductive technology (ART) methods and drugs that help single parents, infertile couples and the Lesbian, gay, bisexual, and transgender (LGBT) community in planning a family.
Key factors such as declining fertility rate, technological advancements in fertility treatments, growth in the median age of first-time motherhood, and rise in obesity, along with consumption of alcohol/cigarettes, are leading to infertility which is eventually driving the market for fertility services. However, high procedural costs of assisted reproductive techniques in developed markets and ethical & social concerns related to ART treatment are hampering the overall growth of the fertility services market. Likewise, reimbursement for fertility treatment serves as an opportunity for the growth of the market.
The Fertility Services Market market is projected to grow at a CAGR of 8.8% from 2016 to 2025.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global fertility services market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on underlying issue, treatment type, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThreat of New Entrants
The threat of new entrants is low in the global fertility services market. Any fertility drug or device manufacturing company or fertility services providers trying to enter the market is required to accept or abide by the mandatory regulatory standards. This market is also characterized by a reasonable degree of brand loyalty, where establishing a brand name is difficult for newcomers.
Bargaining Power of Suppliers
In the global fertility services market, suppliers are raw materials manufacturers for drug or device manufacturing companies. The bargaining power of suppliers is low as there is a high number of suppliers in the fertility services market. Additionally, the switching cost is low as no supplier can influence the prices and exercise control in the industry which makes the bargaining power low.
Threat of Substitutes
The threat of substitutes in the global fertility services market is moderate due to the presence of substitutes such as surrogacy and adoption. However, quality and trust issues for the products and services provided by the players, and excellent service provided by the existing players may restrict the threat by the substitutes to an extent.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global fertility services market. The presence of buyers in the market is growing due to the increasing awareness about the different products, along with the rising prevalence rate of infertility. Additionally, the presence of providers is also growing, which makes the bargaining power of buyers moderate due to the low switching costs.
Intensity of Rivalry
The degree of competition in the global fertility services market is high. The restrained degree of product and service differentiation among existing players increases the intensity of rivalry in the market. Fertility service provider companies are trying to provide cost-effective services to make them more affordable. To overcome the competition, drug and device manufacturing players are engaged in developing a process to lower their manufacturing costs.
Market estimates by geography (2025)
InsightEurope leads with $15.74B by 2025, while North America is projected to grow fastest at a 9.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $2.15B | $2.68B | $3.15B | 4.3% | 7% |
| North America | $4.58B | $7.17B | $10.48B | 9.6% | 24% |
| Asia Pacific | $5.29B | $8.18B | $11.80B | 9.3% | 27% |
| Europe | $7.12B | $10.95B | $15.74B | 9.2% | 36% |
| South America | $1.57B | $2.22B | $2.97B | 7.4% | 7% |
| Total | $20.71B | $31.20B | $44.14B | 8.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$44.14B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Female Infertility | $24.24B | 8.8% | 77% |
| Male Infertility | $19.90B | 8.8% | 54% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Fertility Services Market covering market dynamics, competitive landscape, and strategic outlook.
The Fertility Services Market market is projected to reach $44.14B by 2025, growing at 8.8% CAGR. The Female Infertility segment holds the largest share.
Fertility services are procedures or treatments used to cure genetic and fertility issues and assist with conception. These services include assisted reproductive technology (ART) methods and drugs that help single parents, infertile couples, and the lesbian, gay, bisexual, and transgender (LGBT) community in planning a family.
Factors such as declining fertility rate, technological advancements in fertility treatments, growth in the median age of first-time motherhood, and rise in obesity, along with the consumption of alcohol/cigarettes, are leading to infertility which is eventually driving the market for fertility services. However, high procedural costs of assisted reproductive techniques in developed markets and ethical & social concerns related to the ART treatment is hampering the overall growth of the fertility services market.
Likewise, reimbursement for fertility treatment serves as an opportunity for the growth of the market.
Over the years, fertility services have witnessed high growth due to late marriages, improved contraceptive methods, and the growing number of women prioritizing their careers over starting a family which has also led to the growth in the median age of first-time motherhood. According to Eurostat, the mean age of women in the European Union (EU) on giving birth to their first child has increased from 28.7 in 2013 to 29.1 in 2017. Additionally, according to a report by the United Nations Department of Economics and Social Affairs World Fertility, the average age of first-time pregnancies in women has also risen over the years and was found to be higher in women in their late 20s or early 30s in France. As the median age for first-time motherhood keeps increasing, a growing number of women are expected to face complications in conceiving naturally which also leads to infertility. For instance, according to the National Center for health statistics, in 2015, the fertility rate was 62.5 births per 1,000 women, which dropped by 2% to 60.2 births per 1,000 women in 2017. This downfall in the fertility rate increases the number of women opting for ART treatments, which eventually drives the fertility services market.
The growing availability of funding and reimbursement for certain fertility treatments can be a huge opportunity for the market during the assessment period.
According to the data stated by the IVF Worldwide, in Austria, 70% of the treatment and drug costs for IVF/ICSI are reimbursed by IVF-fund in specific indications.Additionally, in Germany, patients up to 40 years of age for 4 IVF or IVF/ICSI cycles or 2 GIFT are reimbursed. Moreover, according to the ESHRE Fact Sheets 2017, Belgium, Denmark, Netherlands, and Slovenia are reputed to have the most generous reimbursement policies in Europe, with almost full coverage for up to six cycles of IVF. In addition, the extent of state support varies from around 90% in Belgium, France, Greece, Netherlands, and Slovenia, to 20 to 30% in Bulgaria, Romania, and Spain.
Hence, reimbursement for fertility treatment serves is expected to pose significant growth opportunities in the fertility services market during the forecast period.
Despite the growing adoption of fertility treatments, the high cost associated with the fertility treatment is hampering the growth of the market. According to the data mentioned by the Monash IVF Australia, the initial IVF cycle costs approximately USD 3065.22 (AUD 4,461) and subsequent IVF cycle after Medicare safety net costs approximately USD 2676.31 (AUD 3,895). Moreover, according to the CARE Fertility Group Limited (UK), IVF treatments cost USD 3340-3841 (3,000 to 3,450 Euros), Intrauterine Insemination (IUI) costs USD 890-950 (800 to850 Euros), and Intracytoplasmic sperm injection costs USD 1280-1503 (1,150 to 1,350 Euros) in the Europe region. The American Society for Reproductive Medicine (ASRM) lists the average price of an in vitro fertilization (IVF) cycle in the US to be USD 12,400. Thus, the high cost of assisted reproductive techniques to treat infertility is restraining the growth of this market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 108 companies operating in the Fertility Services Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
KITAZATO CORPORATION
Company Headquarters: Tokyo, Japan Founded: 1998 Workforce: ~NA Company Working: Kitazato Corporation is engaged in research, development, and manufacture of medical and biotechnological products for human reproduction. Its Cryotop method for vitrification of oocytes and embryos in all stages of development is renowned worldwide. It offers a broad range of products which include ovarian puncture needles, embryo transfer catheters, insemination catheters, and vitrification systems, among others.
FUJIFILM IRVINE SCIENTIFIC
Company Headquarters: California, US Founded: 1970 Workforce: ~100 Company Working: FUJIFILM Irvine Scientific operated as a subsidiary of Fujifilm Corporation as of June 2018. It is a renowned leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company operates dual cGMP manufacturing facilities in California and Tokyo. It offers a broad range of prenatal, diagnostics, & cytogenetics products, reproductive media products, classical media products, and culture media solutions.
COOK
Company Headquarters: Bloomington, US Founded: 1963 Workforce: ~12,000* (*- Cook Group) Company Working: Cook operates as a subsidiary of Cook Group. It is engaged in the development, manufacture, and distribution of a broad range of medical devices for healthcare systems. It operates through two business divisions which include medical vascular division and medical medsurg division. The products offered by Cook include urological and gynecological devices, biological materials, endoscopic accessories, cardiac rhythm management, and vascular products. It delivers its products in around 135 countries across geographies.
MONASH IVF GROUP
Company Headquarters: Victoria, Australia Founded: 2014 Workforce: ~650 Company Working: Monash IVF Group is a leading provider of assisted reproductive services in Australia and Malaysia. The company operates through two business segments, which include Monash IVF Group Australia and Monash IVF Group International. Monash IVF Group Australia provides assisted reproductive services, ultrasound, and other related services, while Monash IVF Group International provides assisted reproductive services in Malaysia. It has a network of around 40 IVF clinics, ultrasound practices, and service centers across Australia and Malaysia.
VITROLIFE
Company Headquarters: Sweden Founded: 1994 Workforce: ~400 Company Working: Vitrolife is renowned as one of the leading providers of IVF laboratories with high-quality products. It offers a broad range of products for the preparation, cultivation, and storage of human cells, tissues, and organs which include needles, pipettes, incubators, and laser & imaging systems, among others. It operates through four business units including media, time-lapse, disposable devices, and art equipment. It runs production facilities in over ten countries worldwide.
INVO BIOSCIENCE
Company Headquarters: Florida, US Founded: 2007 Workforce: ~N/A Company Working: INVO Bioscience is a major medical device company that offers simplified and low-cost treatments for patients who are diagnosed with infertility. The company is majorly focused on the treatment of infertility through its assisted reproductive technology (ART). INVO is a FDA-approved medical device used for natural in-vivo incubation of eggs and sperms during the fertilization and early embryo development phase which acts as an alternative to traditional Intrauterine Insemination (IUI) and In-Vitro Fertilization (IVF) systems. It has a strong presence across the Americas.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Fertility Services Market